Innocan Pharma Reports Q2 2023 Results Including US$2.706M Increase in Revenues Compared to Q2, 2022

HERZLIYA, Israel and CALGARY, AB, Aug. 25, 2023 /CNW/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4)…